Vertex: The Best Of The Companies Investing In Cystic Fibrosis

By Peter Geschek:On January 31, 2012 a milestone was reached in the history of cystic fibrosis.

While new medicines make progress (or fail) in clinical trials every day with varying levels of attention from the public and press, this week’s

By Rod Raynovich: Vertex Pharmaceuticals Gives Biotech Sector A Turbo Boost

By Ry Frank:Vertex Pharmaceuticals (VRTX) shares recently dropped 20% on the news that its VX-809/Kalydeco Cystic Fibrosis combination therapy data had been inflated. Instead of 46% of the patients in the Phase II studies showing an improvement in lung function of 5% or more, the actual figure was 35%.

By Prohost Biotech:On Monday May 7, 2012, Vertex (VRTX) announced an interim analysis of data from an ongoing Phase 2 study of VX-809 in combination with Kalydeco (ivacaftor).

ByWM Analyst:Vertex Pharmaceuticals Inc. (VRTX) is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives. Founded in 1989, Vertex today employs more than 2,000 people at sites around the world.

Vertex (VRTX) reported interim data on a Phase II study targeting Cystic Fibrosis, which affects 30,000 in the United States and 70,000 worldwide. Previously, the company's KALYDECO drug - which won FDA approval in January - could only be used to treat about 4% of those patients.

By Scott Matusow:Vertex Pharmaceuticals (VRTX) engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.